Literature DB >> 10052811

Serum IFN-inducible protein-10: a new clinical prognostic predictor of hepatocyte death in biliary atresia.

H Kobayashi1, S Narumi, T Tamatani, G J Lane, T Miyano.   

Abstract

PURPOSE: The aim of this study was to determine whether chemokines such as serum IP-10 levels in patients with biliary atresia (BA) correlate with liver function and histology and assess its value as a medium to long-term prediction of prognosis in postoperative BA patients.
METHODS: Thirty postoperative BA patients (mean age, 10.8+/-3.5 years) and eight normal controls (mean age, 10.3+/-3.3 years) were studied. The BA patients were divided into three groups according to liver function. Group I (n = 8) was jaundice free, had normal liver function and no evidence of severe cholangitis or portal hypertension. Group II (n = 12) had moderate liver dysfunction. Group III (n = 10), had severe liver dysfunction. Hepatic histology was assessed using conventional needle biopsy. Serum IP-10 levels were determined using a specific enzyme-linked immunosorbent assay (ELISA).
RESULTS: Serum levels of IP-10 in group III (458.0+/-240.0 pg/mL) were significantly higher than those in group II (233.6+/-126.9 pg/mL; P < .0001). Levels in group II were also significantly higher than those in group I (144.8+/-23.4 pg/mL; P < .05), but there was no significant difference between group I and controls (107.9+/-34.0 pg/mL). Liver biopsy findings showed a progression of fibrosis and mononuclear cell infiltration from group I to group III. There was intimal hyperplasia and swelling of endothelial cells of branches of the hepatic artery in the portal area in group III.
CONCLUSION: Because IP-10 levels correlate closely with histological findings in postoperative BA patients, it would appear to play a specific role in hepatocyte death and hepatic artery changes, thus providing important information about progressive fibrosis in BA patients that facilitates treatment decision making and prediction of prognosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052811     DOI: 10.1016/s0022-3468(99)90197-5

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  6 in total

1.  Serum interleukin-8 in children with biliary atresia: relationship with disease stage and biochemical parameters.

Authors:  Sittisak Honsawek; Voranush Chongsrisawat; Paisarn Vejchapipat; Nutchanart Thawornsuk; Pisit Tangkijvanich; Yong Poovorawan
Journal:  Pediatr Surg Int       Date:  2004-12-24       Impact factor: 1.827

2.  Neutralization of CXCL10 accelerates liver regeneration in carbon tetrachloride-induced acute liver injury.

Authors:  Hiroyuki Yoneyama; Yoshiro Kai; Jun Koyama; Kenji Suzuki; Hiroshi Kawachi; Shosaku Narumi; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2007-12-21       Impact factor: 2.309

3.  [Predictive parameters in children with biliary atresia].

Authors:  J Leonhardt; J F Kuebler; C Turowski; R von Wasielewski; E D Pfister; T Becker; B M Ure; C Petersen
Journal:  Chirurg       Date:  2009-07       Impact factor: 0.955

4.  Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes.

Authors:  K Kakimi; T E Lane; S Wieland; V C Asensio; I L Campbell; F V Chisari; L G Guidotti
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

5.  Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients.

Authors:  Monika Rau; Johannes Schmitt; Thomas Berg; Andreas E Kremer; Bruno Stieger; Katharina Spanaus; Bertram Bengsch; Marta R Romero; Jose J Marin; Verena Keitel; Hartwig Klinker; Hans-Peter Tony; Beat Müllhaupt; Andreas Geier
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

6.  Systemic cytokine profiles in biliary atresia.

Authors:  Wanvisa Udomsinprasert; Tachatra Ungsudechachai; Paisarn Vejchapipat; Yong Poovorawan; Sittisak Honsawek
Journal:  PLoS One       Date:  2022-04-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.